Drug Trial Radar · NCT06164431
Bioavailability Study in Healthy Participants, 200mg Tablets ZSP1273 Versus 200mg Granules ZSP1273
Last checked: Nov 19, 2026Latest source record: Jan 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Nov 23, 2023
Primary completion
Dec 15, 2023
Study completion Dec 22, 2023
Sponsor
- Lead sponsor
- Guangdong Raynovent Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to establish bioavailability of 2 treatments with ZSP1273: 200mg tablets and 200mg granules will be given to healthy Participants under fasting conditions. Bioavailability will be evaluated and verified on the basis of pharmacokinetic data.
Conditions
- Bioequivalence
Interventions
ZSP1273 tabletDrug
Participants receive ZSP1273 tablet orally.
zsp1273 granulesDrug
Participants receive ZSP1273 granules orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax)Time frame: Day 1 to Day 20
- Area under the concentration-time curve from time zero to infinity (AUCinf)Time frame: Day 1 to Day 20
- Area under the concentration-time curve from time zero to last time of quantifiable concentration (AUClast)Time frame: Day 1 to Day 20
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Hospital of Chinese Medicine
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.